Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Atrium Therapeutics (Nasdaq: RNA) awarded inducement equity grants on April 20, 2026 to seven newly hired non-executive employees under a new 2026 Inducement Plan adopted in April 2026.

The Awards total 101,250 stock options (exercise price $14.30) and 50,625 restricted stock units. Options and RSUs vest 25% after one year, then monthly or annual installments thereafter, subject to continued service. The Board's Human Capital Management Committee approved the grants under Nasdaq Listing Rule 5635(c)(4).

AI-generated analysis. Not financial advice.

News Market Reaction – RNA

-5.38%

3 alerts

-5.38% News Effect

+19.1% Peak Tracked

-$14M Valuation Impact

$244.74M Market Cap

0.0x Rel. Volume

On the day this news was published, RNA declined 5.38%, reflecting a notable negative market reaction. Argus tracked a peak move of +19.1% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $14M from the company's valuation, bringing the market cap to $244.74M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Current share price: $14.30 Stock options granted: 101,250 shares RSUs granted: 50,625 shares +5 more

8 metrics

Current share price $14.30 Closing price on grant date, used as option exercise price

Stock options granted 101,250 shares Aggregate non-qualified stock options under 2026 Inducement Plan

RSUs granted 50,625 shares Aggregate restricted stock units for new employees

Number of employees 7 individuals Non-executive new hires receiving inducement awards

Option exercise price $14.30 per share Equal to Nasdaq-reported closing price on grant date

Initial vesting cliff 25% Portion of options and RSUs vesting on first anniversary

Option vesting schedule 36 monthly installments After first-year cliff, subject to continued service

RSU later vesting 3 annual installments Remaining RSUs vest yearly after first anniversary

Market Reality Check

Price: $11.80 Vol: Volume 548,022 is 1.03x t...

normal vol

$11.80 Last Close

Volume Volume 548,022 is 1.03x the 20-day average (532,208). normal

Technical Shares at $14.30 are trading below the 200-day MA of $49.42 and are 80.43% below the 52-week high of $73.06.

Peers on Argus

RNA slipped 0.76% while close peers showed mixed moves: CRSP +0.96%, PTCT +0.44%...

RNA slipped 0.76% while close peers showed mixed moves: CRSP +0.96%, PTCT +0.44%, TGTX +5.09%, MRUS -7.08%, NUVL +0.78%. No coordinated sector momentum flagged.

Historical Context

5 past events · Latest: Feb 27 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 27	Company launch / funding	Positive	-79.7%	Atrium launched with ~$270M cash and two lead RNA candidates.
Feb 26	Conference presentations	Positive	-79.7%	Multiple upcoming MDA conference presentations on RNA programs announced.
Feb 23	Special meeting timing	Neutral	+0.1%	Adjournment and reconvening of special meeting for merger conditions.
Feb 18	Clinical data update	Positive	+0.0%	NEJM publication of positive Phase 1/2 MARINA trial results in DM1.
Feb 02	Spin-off record date	Neutral	+0.3%	Record date set for Atrium spin-off tied to Novartis acquisition.

Pattern Detected

Recent major corporate and clinical milestones often saw muted or negative price reactions, including a sharp selloff around the launch/spin structure.

Recent Company History

Over the last few months, RNA-related news has focused on corporate restructuring and pipeline progress. On Feb 2, Avidity announced a spin-off record date. A special meeting for the Novartis transaction followed on Feb 23. Atrium’s launch with about $270 million cash and two lead RNA cardiomyopathy programs was announced on Feb 27, yet the stock fell 79.74% over 24 hours. Earlier in February, positive MARINA Phase 1/2 data barely moved the price. Today’s inducement grants fit into post-spin company build-out rather than a major value inflection.

Market Pulse Summary

The stock moved -5.4% in the session following this news. A negative reaction despite the largely ro...

Analysis

The stock moved -5.4% in the session following this news. A negative reaction despite the largely routine nature of inducement grants could fit a pattern where the stock traded weakly around corporate events. Prior news such as Atrium’s launch with about $270 million cash still coincided with a 79.74% decline, showing sensitivity to structure and valuation. With options on 101,250 shares and 50,625 RSUs granted at $14.30, some investors might have focused on incremental dilution or broader sentiment rather than the hiring signal.

Key Terms

non-qualified stock options, restricted stock units, par value, Nasdaq Listing Rule 5635(c)(4), +2 more

6 terms

non-qualified stock options financial

"The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares..."

Non-qualified stock options are a type of employee benefit that gives individuals the right to buy company shares at a set price, usually lower than the market value, within a certain period. Unlike other options that may have special tax advantages, these options are taxed as income when exercised, which can affect how much money the employee or investor ultimately gains. They are important because they can influence company compensation strategies and impact the financial outcomes for employees and investors.

restricted stock units financial

"...and restricted stock units for an aggregate of 50,625 shares of the Company's common stock..."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

par value financial

"...shares of the Company's common stock, par value $0.001 per share..."

Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.

Nasdaq Listing Rule 5635(c)(4) regulatory

"...as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

inducement grants financial

"...announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan..."

Inducement grants are special awards of shares or stock options given to new employees to encourage them to join a company or accept a new role. They act like a welcome bonus, providing an extra incentive to attract talent. For investors, these grants can impact a company's costs and share structure, influencing the value of their investments.

restricted stock units (RSUs) financial

"...and restricted stock units for an aggregate of 50,625 shares of the Company's common stock..."

Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.

AI-generated analysis. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 20, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company") today announced it awarded inducement grants on April 20, 2026 under the Company's 2026 Employment Inducement Incentive Award Plan (the "2026 Inducement Plan") as a material inducement to the employment of seven non-executive individuals newly hired by the Company.

The employees received, in the aggregate, non-qualified stock options to purchase 101,250 shares of the Company's common stock, par value $0.001 per share, with an exercise price of $14.30 per share, the closing price of the Company's common stock as reported by Nasdaq on the effective date of the grant, 25% of which will vest and become exercisable on the first anniversary of the grant date, and the remaining underlying shares will vest in 36 substantially equal installments each month thereafter, subject to the employee's continued service with the Company through each applicable vesting date; and restricted stock units for an aggregate of 50,625 shares of the Company's common stock, 25% of which will vest in the first anniversary of the grant date, and the remaining underlying shares will vest in three substantially equal installments each year thereafter, subject to the employee's continued service with the Company through each applicable vesting date, or collectively, the "Awards."

All of the above-described Awards were granted outside of the Company's stockholder-approved equity incentive plans pursuant to the 2026 Inducement Plan, which was adopted by the Company's board of directors (the "Board") in April 2026. The Awards were approved by the Board's Human Capital Management Committee, which is comprised solely of independent directors, as a material inducement to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atrium Therapeutics, Inc.

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides. Atrium Therapeutics' platform is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from delivery to the skeletal muscle and applies it for efficient delivery to the heart overcoming challenges associated with non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 and ATR 1086, and two undisclosed research targets in rare cardiomyopathies. For more information about our RNA delivery platform, development pipeline and people, please visit https://atriumtherapeutics.com/ and engage with us on LinkedIn.

View original content to download multimedia:https://www.prnewswire.com/news-releases/atrium-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302748022.html

SOURCE Atrium Therapeutics

FAQ

What inducement grants did Atrium Therapeutics (RNA) issue on April 20, 2026?

Atrium issued options for 101,250 shares and RSUs for 50,625 shares as inducement awards. According to the company, these awards were granted under the 2026 Inducement Plan to seven newly hired non-executive employees and approved by the Board committee.

What is the exercise price and vesting schedule for RNA's April 20, 2026 option grants?

The options have an exercise price of $14.30 per share and vest 25% after one year. According to the company, the remaining option shares vest in 36 substantially equal monthly installments subject to continued service.

How do the restricted stock units granted by Atrium (RNA) on April 20, 2026 vest?

The RSUs vest 25% on the first anniversary, then in three substantially equal annual installments thereafter. According to the company, vesting is subject to the employees' continued service through each applicable vesting date.

Under which plan and Nasdaq rule were RNA's inducement awards granted in April 2026?

The awards were granted outside stockholder-approved plans under the 2026 Inducement Plan adopted in April 2026. According to the company, the grants were made as material inducements per Nasdaq Listing Rule 5635(c)(4).

Who approved the inducement awards for Atrium Therapeutics (RNA) on April 20, 2026?

The Board's Human Capital Management Committee approved the awards, and the committee is comprised solely of independent directors. According to the company, approval was in accordance with Nasdaq Listing Rule 5635(c)(4).